Celyad Oncology SA American Depositary Shares
CYAD
CYAD was delisted on the 18th of May, 2023.
8 hedge funds and large institutions have $16.8M invested in Celyad Oncology SA American Depositary Shares in 2022 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 3 closing their positions.
20% less funds holding
Funds holding: 10 → 8 (-2)
31% less capital invested
Capital invested by funds: $24.2M → $16.8M (-$7.45M)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$44.7K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$1.45K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
-$65K |
| 2 |
Jane Street
New York
|
-$44K |
| 3 |
Morgan Stanley
New York
|
-$12.1K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$4K |
| 5 |
HF
HRT Financial
New York
|
-$3.99K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
FIG
1
Fortress Investment Group
New York
| $15.8M | – | – | – |
|
2
Osaic Holdings
Scottsdale,
Arizona
| $777K | – | – | – |
|
|
HF
3
HRT Financial
New York
| $88K | -$3.99K | -1,305 | -3% |
|
|
4
Morgan Stanley
New York
| $49K | -$12.1K | -3,958 | -17% |
|
5
Wells Fargo
San Francisco,
California
| $42K | -$3.1K | -1,015 | -5% |
|
|
6
Citadel Advisors
Miami,
Florida
| $35K | +$44.7K | +14,598 | New |
|
|
7
UBS Group
Zurich,
Switzerland
| $10K | +$1.45K | +474 | +13% |
|
8
National Bank of Canada
Montreal,
Quebec, Canada
| $8K | – | – | – |
|
|
TSS
9
Two Sigma Securities
New York
| – | -$65K | -17,786 | Closed |
|
|
10
Jane Street
New York
| – | -$44K | -11,122 | Closed |
|
|
TRCT
11
Tower Research Capital (TRC)
New York
| – | -$4K | -1,225 | Closed |
|
CYAD Hedge Fund Activity: Q1 2022 in Review
8 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Celyad Oncology SA American Depositary Shares (CYAD) for Q1 2022, worth a combined $16.8M — down 31% from $24.2M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of CYAD and 1 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 1 added.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $44.7K. The largest seller was Two Sigma Securities, exiting entirely with an estimated $65K sold.
- 8 institutional investors held Celyad Oncology SA American Depositary Shares (CYAD) as of Q1 2022, down from 10 in Q4 2021.
- Funds reported $16.8M of Celyad Oncology SA American Depositary Shares stock for Q1 2022, down 31% quarter-over-quarter.
- 1 fund opened new Celyad Oncology SA American Depositary Shares positions in Q1 2022 and 3 closed out, a net change of -2 holders.
- The largest Celyad Oncology SA American Depositary Shares buyer in Q1 2022 was Citadel Advisors, an estimated $44.7K added.
- The largest Celyad Oncology SA American Depositary Shares seller in Q1 2022 was Two Sigma Securities, an estimated $65K sold.
Based on aggregated 13F filings for Q1 2022.